Novo CEO calls Wegovy problems "a perfect storm," will not move production in-house

A productions halt at a US-based subcontractor has been a fly in the ointment for the launch of Novo’s obesity drug Wegovy. However, CEO Lars Fruergaard Jørgensen isn’t considering bringing more of the production chain in-house in the future.

Photo: Novo Nordisk / PR

Serious production problems at one of Novo Nordisk’s subcontractors have meant that the Danish pharmaceutical company won’t be able to meet the full demand of its newly launched obesity treatment, Wegovy.

The contract manufacturer was behind filling a significant portion of the injector pens used in the obesity treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs